#United States #Plymouth Meeting #Cancer Fatigue #JNCCN #methylphenidate

New Insights on Psychostimulants for Cancer Fatigue Relief

A recent study published in the JNCCN—Journal of the National Comprehensive Cancer Network—has provided fresh insights regarding a well-known medication's potential to alleviate cancer-related fatigue. This analysis, appearing in the May 2026 edition, represents the most thorough evaluation to date of methylphenidate-type psychostimulants, which work by enhancing the levels of dopamine and norepinephrine in the brain.

Fatigue is a common and often debilitating symptom experienced by nearly three-quarters of individuals undergoing cancer treatment, according to various estimates. Despite its prevalence, it remains one of the most neglected health concerns in oncology. The compelling findings from this comprehensive meta-analysis signal a significant step forward in addressing this challenge.

The study analyzed data sourced from nine randomized clinical trials, focusing exclusively on methylphenidate (MPH) and dexmethylphenidate (d-MPH). The researchers discovered that patients receiving these medications reported substantial improvements in fatigue scores when compared to those given placebo treatments. Notably, these benefits appeared to grow over time, particularly becoming more pronounced around the five-week mark.

Dr. Bruno Almeida Costa, the lead author and a researcher from The University of Texas MD Anderson Cancer Center, remarked on the importance of this timing, emphasizing that the medication not only improved patients' energy levels but also positively influenced their overall functionality. He advocates for integrating methylphenidate into a broader treatment strategy for managing fatigue rather than viewing it as a standalone solution. While he acknowledges the importance of additional interventions such as exercise, cognitive-behavioral therapy, and mind-body practices—which often require 8 to 12 weeks of commitment for optimal results—he believes that methylphenidate can provide essential relief during this period.

The analysis included a total of 823 patients who participated in these double-blind, placebo-controlled trials published between May 2006 and July 2024. The primary metric utilized for assessing fatigue was the FACIT-F scale, a validated 13-item patient-reported questionnaire. Importantly, the study found no significant increase in side effects associated with methylphenidate and its counterpart compared to placebo, though vigilant patient selection and ongoing monitoring practices remain crucial.

Concerns are rising regarding younger adults being diagnosed with cancer at an increasing rate. According to Dr. Costa, this demographic often leads busy lives filled with career and family obligations. Fatigue, therefore, can severely disrupt their daily functioning, making effective management crucial. The findings highlight the potential role that methylphenidate may play in preserving these individuals’ daily activities and facilitating continuity in their cancer treatment journey.

Dr. Chandana Banerjee, MPA, HMDC, FAAHPM, Vice-Chair of the NCCN Clinical Practice Guidelines in Oncology for Cancer-Related Fatigue, commented on the emerging evidence supporting the use of MPH/d-MPH. She noted that strategic patient selection and careful monitoring can significantly enhance treatment outcomes, making modest effects clinically impactful.

The NCCN Guidelines® for addressing cancer-related fatigue now include considerations for using methylphenidate under specific circumstances, stressing the importance of cautious dosage and exploring any underlying health issues.

For more in-depth insights, you can access the full study, titled “Methylphenidate-Type Psychostimulants for Cancer-Related Fatigue: Updated Meta-Analysis of Randomized Controlled Trials” at JNCCN.org.

In an exciting transition, JNCCN has announced that starting from July 2026, it will only publish digitally, ceasing its print editions altogether. This change aims to facilitate quicker access to impactful research and enhance information dissemination within the oncology community.

About JNCCN: More than 25,000 oncologists and cancer care professionals across the United States regularly consult the JNCCN for the latest advancements in oncology health services and research. Through its peer-reviewed journal, JNCCN aims to deliver groundbreaking insights into patient care and cancer treatment guidelines.

About the National Comprehensive Cancer Network: The NCCN is a non-profit organization that comprises a network of leading cancer centers committed to enhancing the quality of cancer prevention and care. The NCCN Guidelines provide evidence-based recommendations to support clinicians in delivering effective cancer treatment and supportive services.